CareDx, Inc. is dedicated to improving the lives of organ transplant patients through noninvasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx strives to stay at the forefront of organ transplant surveillance solutions.
KidneyCare is a comprehensive management tool to assist clinicians in proactive and standardized surveillance of transplant recipients. KidneyCare Combines clinically-validated AlloSure test with AlloMap-Kidney and iBox for multi-modality testing and prognostic information.
AlloSure is the first and only non-invasive test that assesses organ health by directly measuring allograft injury. AlloSure can accurately determine active rejection, enabling better management of your kidney transplant patients.
HeartCare is a comprehensive rejection surveillance for heart transplant recipients. HeartCare includes both AlloMap and AlloSure-Heart to provide valuable information about distinct biological processes.
AlloMap is a non-invasive blood test that helps physicians identify the risk of acute cellular rejection in heart transplant recipients.
Look for CareDx at the following events:
American Transplant Congress 2019
Boston, MA, United States
June 1-5, 2019
HFSA - Heart Failure Society of America
Philadelphia, PA, United States
September 14-17, 2019
ASHI 2019 - Banff/ASHI Joint Conference
Pittsburgh, PA, United States
September 23-27, 2019
AST Fellows Symposium
Dallas, TX, United States
September 27-29, 2019